FDA Grants Traditional Approval To Selpercatinib For The Treatment Of Advanced Or Metastatic Solid Tumors

The FDA has granted traditional approval to the drug Selpercatinib (brand name Retevmo) for the treatment of both adults and children aged 2 and older who have advanced or metastatic solid tumors. This approval applies specifically to patients whose tumors carry a specific genetic change known as a “RET gene fusion,” which has been confirmed by an FDA-approved test. This is an important update, as it upgrades the drug from an earlier “accelerated” approval, based on further evidence confirming the treatment’s effectiveness in patients who have either not responded to previous systemic therapies or have no other satisfactory treatment options available.

Selpercatinib works as a targeted therapy. Instead of attacking all rapidly dividing cells like some older chemotherapy drugs, it specifically homes in on and blocks the activity of the mutated RET protein that is helping the cancer grow. By focusing on this specific genetic vulnerability—often called a “biomarker”, doctors can use the drug to stop tumor growth in a variety of different cancer types that share this same genetic signature. This approach offers a more precise option for patients who previously had very limited ways to treat their specific type of cancer.

Read the full article